Literature DB >> 6312005

Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression.

S Leisti, O Koskimies.   

Abstract

Glucocorticoid therapy has been effective in inducing remission in the majority of children with primary nephrotic syndrome. However, glucocorticoid-induced adrenocortical suppression is associated with early relapse, whereas normal adrenocortical function seems to delay the subsequent relapse. We analyzed 201 episodes of prednisone treatment in 47 children with steroid-sensitive nephrotic syndrome by the life-table method. The effect of partial cortisol substitution was studied as well. Adrenocortical function was determined by a two-hour ACTH test. A response of 50% to 100% of the minimum normal response was diagnosed as "moderate" suppression, and a response of less than 50% as "severe." Post-prednisone adrenocortical function was normal in 99 episodes (49%). Adrenocortical suppression occurred in 102 episodes; of these, 68 were considered moderate and 34 severe. Adrenocortical suppression increased both the initial relapse rate and the final risk of a relapse. Severe suppression was always associated with a relapse, the longest remission time being 0.5 year. In moderate suppression, several long, relapse-free intervals were observed, but the risk of relapse was still higher than in episodes with normal adrenocortical function. Cortisol substitution possibly decreased the risk of a relapse after severe adrenocortical suppression, but not after moderate suppression.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6312005     DOI: 10.1016/s0022-3476(83)80582-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.

Authors:  Menka Yadav; Aditi Sinha; Priyanka Khandelwal; Pankaj Hari; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2018-09-07       Impact factor: 3.714

2.  Pharmacokinetics of prednisolone in children with nephrosis.

Authors:  P F Miller; C J Bowmer; J Wheeldon; J T Brocklebank
Journal:  Arch Dis Child       Date:  1990-02       Impact factor: 3.791

3.  Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.

Authors:  Asiri S Abeyagunawardena; R S Thalgahagoda; Pathum V Dissanayake; Shamali Abeyagunawardena; Y A Illangasekera; Umeshi I Karunadasa; Richard S Trompeter
Journal:  Pediatr Nephrol       Date:  2017-03-24       Impact factor: 3.714

Review 4.  The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies.

Authors:  J Brodehl
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

5.  Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors:  J H Ehrich; J Brodehl
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

6.  Adrenocortical suppression increases the risk of relapse in nephrotic syndrome.

Authors:  Asiri S Abeyagunawardena; Peter Hindmarsh; Richard S Trompeter
Journal:  Arch Dis Child       Date:  2007-02-06       Impact factor: 3.791

7.  Aspects of Brazilian paediatric nephrology.

Authors:  J S Diniz
Journal:  Pediatr Nephrol       Date:  1988-04       Impact factor: 3.714

Review 8.  Women, kidney disease, and pregnancy.

Authors:  Andrew Smyth; Milan Radovic; Vesna D Garovic
Journal:  Adv Chronic Kidney Dis       Date:  2013-09       Impact factor: 3.620

9.  Steroid Regimen for Children with Nephrotic Syndrome Relapse.

Authors:  Anna Elizabeth Williams; Rasheed A Gbadegesin
Journal:  Clin J Am Soc Nephrol       Date:  2021-01-21       Impact factor: 8.237

Review 10.  Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome.

Authors:  Martin T Christian; Andrew P Maxted
Journal:  Pediatr Nephrol       Date:  2021-02-20       Impact factor: 3.651

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.